生物技术公司Viking Therapeutics(VKTX.US)公布，其口服减肥药物的一期试验结果好於预期，股价周一盘前曾涨逾5%。 公司指，针对 ...

在没有上市药物的生物科技公司中，Viking当前的资产负债情况非常优越。从投资的角度分析，该股未来增发股票导致股权被稀释的风险很低，承受临床项目失败的抗风险能力很强。即使试验数据不佳可能导致股价回落，但不会对财务造成重大的冲击。

With a gain of more than 531% over the last 12 months, shares of Viking Therapeutics (NASDAQ: VKTX) are a hot commodity, to ...

The pharmaceutical company Viking has recently become one of the most volatile stocks on Wall Street due to the announcement ...

The Company is also evaluating an oral tablet formulation of VK2735 (ClinicalTrials.gov Identifier: NCT05203237). Phase 1 trial results demonstrated up to a 3.3% placebo-adjusted mean weight reduction ...

AstraZeneca’s new obesity pill, licensed from China’s Eccogene last year, has shown initial promise in early-stage trials.

Shares of Viking Therapeutics (NASDAQ: VKTX) fell on Monday, Nov. 4, despite some encouraging new data. Over the weekend, the ...

很明显减肥药物淘金热只会愈演愈烈。对减肥药物的极高需求提供了相当大的机会。投资者对Viking打入减肥药市场的潜力表示看好，今年该公司股价已上涨三倍。据预测，到2030年，减肥药市场规模将达到1300亿美元。投资者不应该对Viking所面临的日益激烈的竞争感到气馁，这家生物技术公司显然拥有一种有效的药物，并且在开发以及商业化药物方面进展顺利。

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock ...

Viking Therapeutics’ GLP-1 pill candidate for treating obesity showed promise in its latest trial results, the clinical-stage ...

Viking Therapeutics shares climbed 9% on Monday after the drug developer's oral obesity treatment helped reduce body weight ...

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Viking Therapeutics (VKTX – Research ...